Shares of Zai Lab Ltd (ZLAB) tumbled 6.45% in pre-market trading on Thursday following the release of its third-quarter financial results, which fell short of analysts' expectations. The biopharmaceutical company's disappointing earnings report has sparked concerns among investors about its financial performance.

According to the earnings flash, Zai Lab reported a loss of $0.33 per American Depositary Share (ADS) for the third quarter, wider than the FactSet consensus estimate of a $0.29 loss. This represents a $0.04 miss on the bottom line, indicating that the company's expenses may have been higher than anticipated or its operational efficiency lower than expected.

Adding to investors' worries, Zai Lab's revenue for the quarter came in at $116.1 million, significantly below the FactSet estimate of $141.7 million. This substantial revenue miss of approximately $25.6 million suggests that the company's product sales or partnerships may have underperformed during the quarter. The combination of wider losses and lower-than-expected revenue has led to the sharp pre-market decline in Zai Lab's stock price as investors reassess the company's near-term growth prospects and financial health.